1. Survival according to recurrence patterns after resection for transplantable hepatocellular carcinoma in HBV endemic area: Appraisal of liver transplantation strategy
- Author
-
Yeon Seok Seo, Bora Keum, Na Yeon Han, Tae Hyung Kim, Young Sun Lee, Eun Sun Kim, Yoon Tae Jeen, Chang Duck Kim, Hyuk Soon Choi, Yoo Ra Lee, Ji Hoon Kim, Hyung Joon Yim, Sang Jun Suh, Dong-Sik Kim, Hoon Jai Chun, Hong Sik Lee, Hyun Gil Goh, Chung Gyo Seo, Soon Ho Um, Yoo Jin Lee, and Sun Young Yim
- Subjects
Hepatitis B virus ,medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Gastroenterology ,Endemic area ,Liver transplantation ,Milan criteria ,medicine.disease ,medicine.disease_cause ,Resection ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Internal medicine ,medicine ,Initial treatment ,030211 gastroenterology & hepatology ,Risk factor ,business - Abstract
Summary Background and aims Since there is a shortage of liver donors, we investigated recurrence patterns and outcomes after liver resection (LR) to determine the feasibility of salvage liver transplantation (SLT). Methods We analyzed 468 patients with hepatocellular carcinoma (HCC) within the Milan criteria (MC) who were mainly associated with Hepatitis B virus infection (76.3%) and had undergone curative LR as an initial treatment. Results The overall survival (OS) rates were 86.6% and 67.4% at 5 and 10 years after LR, respectively. During a median follow-up of 59 months, 211 patients experienced recurrences including 175 (37.4%) within MC and 36 (7.7%) beyond MC. Survival was lowest in patients with beyond MC-recurrence followed by within MC- and no-recurrence groups (26.5%, 86.6%, and 94.7% at 5 years, respectively, P Conclusion Curative LR achieved a 5-year survival of > 85% in patients with transplantable HCC, but early SLT after recurrence within MC is advocated because of poor survival and high risk of progression thereafter. Further, prophylactic LT could be considered for those with high risk of recurrence.
- Published
- 2020